Major depression during interferon-α treatment: vulnerability and prevention by Lotrich, Francis E.
ajor Depressive Disorder (MDD) is common,
costly,
1-3 and notably heterogeneous. Unfortunately, the
accurate prediction and subsequent prevention of MDD
episodes (MDEs) has been challenging. There is evi-
dence that MDEs are variously associated with elevated
psychosocial stress, the postpartum period, hypothy-
roidism, circadian changes, cerebrovascular disease,
administration of inflammatory cytokines such as inter-
feron-α (IFN−α), etc. Therefore, one approach for pre-
venting a MDE could be to avoid stressful circum-
stances, pregnancy, cerebrovascular disease, and/or
IFN−α therapy. However, this is often impractical.
Thankfully, most people who are exposed to these vari-
ous“triggers” do not develop MDD. 
Identifying modifiable markers of risk in specifically
vulnerable people, and then mitigating these before
MDD occurs, could be a better approach for prevent-
ing MDD. However, identifying causal risk factors that
pre-exist in nondepressed people requires prospective
studies, and the incidence of an MDE over 1 year is less
than 2%.
4-6The necessarily large epidemiologic studies
have successfully identified predictive risk markers
such as gender, age, cohort, family history, marital sta-
tus, socioeconomic status, and stressful life events
6,7—
but each of these is difficult or impossible to mitigate.
Another strategy is needed for prospectively assessing
nondepressed people for modifiable risk factors, and a
related strategy is needed for examining whether
specifically alleviating these vulnerabilities prevents
MDE.
417
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Major Depressive Disorder (MDD) during interferon-α
(IFN−α) treatment can occur within a few months of ther-
apy, and shares many homologies with other forms of
MDD. Most patients are resilient to the side effect of inter-
feron-induced depression (IFN-MDD), but 15% to 40% are
vulnerable. Several studies have employed antidepressants
to prevent the incidence of an IFN-MDD episode, and the
results suggest that prophylactic antidepressants may be
specifically useful in those with pre-existing subthreshold
depressive symptoms and/or a history of prior MDD
episodes. Several other potential markers of vulnerability
for IFN-MDD have been implicated in assessments of non-
depressed patients before they start IFN−α. These include
poor sleep quality, premorbid elevations in inflammatory
cytokines, genetic polymorphisms in the serotonin system,
personality, and social support. The interplay of these fac-
tors strongly predicts who is at risk for IFN-MDD, and indi-
cates several potentially modifiable targets for the per-
sonalized prevention of IFN-MDD. 
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MDD during IFN-α therapy
One approach for delineating modifiable risk factors is to
examine homogeneous groups of people who are defini-
tively known to soon be exposed to a specific MDD-evok-
ing situation. Towards this end, patients receiving IFN−α
may be ideal candidates for examining MDD vulnerabil-
ity.
8-12 MDD during IFN−α treatment (IFN-MDD) typi-
cally develops within the first 2 or 3 months of adminis-
tration,
13-17 and occurs in about 15% to 40% of patients.
18
Thus, prospectively assessing IFN-MDD onset is feasi-
ble—and consequently it may be possible to determine
predictive modifiable vulnerabilities in the 15% to 40%
who subsequently develop IFN-MDD. 
Of course, it is conceivable that IFN-MDD is unique, and
that other forms of MDD are completely distinct from it.
However, several lines of evidence indicate that IFN-
MDD may successfully inform us about MDD in general.
First, a variety of studies have found a robust relationship
between IFN−α and MDE, including those demonstrat-
ing a dose-response relationship,
19,20 studies with control
groups,
16,19-21 and prospective documentations of worsen-
ing depression during IFN−α treatment with a return to
baseline mood after discontinuation.
23-25Thus, IFN-MDD
is a replicable finding in prospective studies. Second, IFN-
MDD has phenomenological resemblance to MDD diag-
nosed in other situations.
21-24That is, IFN-MDD is not sim-
ply fatigue and malaise but—similarly to
MDD—involves anhedonia, depressed mood, irritability,
anxiety, social withdrawal, poor concentration, altered
sleep, personality changes, and suicidal ideation (Table I). 
Third, MDD and IFN-MDD may share similar patho-
physiologic mechanisms, as indicated by various inde-
pendent lines of investigation:
￿ Many inflammatory cytokines are elevated during
MDD.
51-53
￿ Psychosocial stress can increase the levels of inflam-
matory cytokines.
54,55
￿ IFN−α and other cytokines can affect central
monoaminergic systems plausibly involved in MDD.
56-63
￿ Peripheral cytokines and IFN−α have access to the
CNS through a variety of routes in addition to being
synthesized in the brain.
64-66
￿ Endogenous IFN−α mRNA can be induced in the cor-
tex, hippocampus, and hypothalamus, with correlated
changes in behavior in animal models of depression.
64,67
￿ Systemic administration of IFN−α and other cytokines
can affect amotivation and anhedonia behaviors in
rodent models of depression.
68-75
￿ Once IFN-MDD is diagnosed, it responds to treat-
ments that are effective for idiopathic MDD, ranging
from selective serotonin reuptake inhibitors (SSRIs)
and tricyclic antidepressants to electroconvulsive ther-
apy,
15,76-85 with about 79% to 85% of patients respond-
ing to antidepressants.
86,87
￿ IFN−α administration can influence frontal lobe and
anterior cingulate function,
88,89 dopaminergic activity,
60
and serotonergic function,
90-93—all of which may con-
tribute to the development of depression in a manner
homologous to other types of MDD. 
Of further public health significance, the use of IFN−α is
not rare. Almost 2% of the U.S. currently has chronic
hepatitis C (HCV).
94 IFN−α is the only FDA-approved
treatment for HCV,
95,96 whereas about 170 million people
worldwide have been infected with HCV.
97 Supporting
IFN−α’s widespread use, untreated chronic HCV can
lead to cirrhosis, hepatocellular cancer, and liver failure,
Selected abbreviations and acronyms
IFN- interferon-alpha
IL interleukin
MDD major depressive disorder
SSRI selective serotinin reuptake inhibitor
Signs and symptoms MDD IFN-MDD
Anhedonia Yes Yes
24-29
Depressed mood Yes Yes
26-30
Sleep problems Yes Yes
26,27,29-32
Amotivation Yes Yes
27
Decreased appetite Yes Yes
27,28,30
Concentration changes Yes Yes
27-29,33-36
Tearfulness Yes Yes
27
Social withdrawal Yes Yes
27
Guilt Yes Yes
26
Interpersonal sensitivity Yes Yes
37
Suicidal ideation Yes Yes
27,29,38
Associated symptoms
Irritability Yes Yes
26,27,29,30,39
Increased neuroticism Yes
40,41 Not known
Care-seeking behaviors Yes
42 Seen in illness behavior
43
Dependency/acting out 
regression/somatization Yes
44,45 Seen in illness behavior
46-50
Table I. Comparison of Major Depressive Disorder  (MDD) and inter-
feron-α depressive disorder (IFN-MDD) during interferon-α treat-
ment.
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resulting in about 10 000 deaths per year in the US,
98 a
rate which exceeds that from acquired immunodeficiency
syndrome.
99 Unfortunately, IFN-MDD can potentially
result in suicide,
38 dose reduction with risk for viral
relapse,
16 discontinuation of treatment,
100,101 and lower
quality of life.
102,103Therefore, the two rationales for pre-
venting IFN-MDD are that (i) this is a common and dis-
abling syndrome; and (ii) it may be and ideal strategy for
informing us about ways to prevent MDD in general.
Prevention studies of IFN-MDD
A few prophylactic trials using selective serotonin reup-
take inhibitors (SSRIs) have transpired. These preven-
tion studies initiated SSRIs in patients who were not cur-
rently experiencing any MDE prior to beginning the
IFN−α therapy (Table II).
80,83,85,104-107The first randomized
placebo-controlled trial (RCT) was done in patients with
metastatic melanoma, using very high doses of intra-
venous IFN−α. This initial study found strong evidence
for prevention of IFN-MDD, with only 2/18 paroxetine-
treated patients (11%) developing IFN-MDD, as com-
pared with 45% of the placebo-treated group.
80 Similarly,
in three open-label trials of prophylactic SSRIs given to
nondepressed HCV patients, only 3/32 patients (9%)
developed IFN-MDD, despite all 32 patients having a
prior history of affective disorder. These open-label stud-
ies are thus consistent with this RCT study, supporting
the conclusion that preventative treatment with SSRIs
may be useful. 
However, two small RCT studies have now been com-
pleted in patients with HCV (Table II). Neither study
found IFN-MDD prevention.
85,106 Prophylactic SSRIs may
therefore not be universally effective. Despite these two
negative findings, one of these studies did report that
24/29 patients in the placebo group developed elevated
depression symptoms compared with 10/23 in the parox-
etine group.
106Additionally, further exploratory analyses
indicated that prevention may have been most success-
ful for those subjects who already had high pretreatment
baseline levels of depressive symptoms.
106This would be
an example of “indicated prevention” whereby treating
“subthreshold” depression symptoms may prevent sub-
sequent worsening to full categorical MDD.
108-111 It has
been well-replicated that higher levels of pretreatment
depression symptoms are associated with the develop-
ment of IFN-MDD,
18,112-115 and these subthreshold symp-
toms may be an appropriate target for using preventive
SSRIs. Another open possibility is that prophylactic
SSRIs specifically prevented IFN-MDD in those with
past histories of MDD in remission. This type of preven-
tion would be consistent with the use of antidepressants
to prevent recurrence of remitted MDD.
116-119
To explore this latter possibility, we prospectively fol-
lowed 31 patients who were not depressed at the onset
of IFN−α therapy (as determined using a Structured
Clinical Interview of DSM-IV Axis I diagnoses). All of
these patients had no MDEs within 6 months prior to
starting IFN−α, but they did have a history of past
MDD. Ten of these patients were stably taking SSRIs.
Only 20% (2/10) of the patients on SSRIs developed
IFN-MDD, while 47.6% (10/21) not on antidepressants
did. These results are numerically similar to the RCTs
reviewed above. This very limited analysis suggests a
SSRI Trial type (N) Baseline characteristics Diagnosis Comments
Paroxetine
80 RCT 18 vs 20 Melanoma patients; average HAM-D>5 DSM-IV Prevented IFN-MDD. 2/18 vs 9/20
Paroxetine
85 RCT 14 vs 19 Average HAM-D<3 DSM-IV Did not prevent IFN-MDD. 5/14 vs 6/19
Paroxetine
106 RCT 23 vs 29 Median MADRS = 3 DSM-IV or Did not prevent IFN-MDD overall 3/23 vs 6/29
MADRS>15 Benefit for patients with baseline MADRS >3
Citalopram
104 Open label 10 vs 0 MDD history in remission HAM-D =17  1/10 had recurrence of IFN-MDD
Paroxetine or Open label 8 vs 0 History of previous IFN-MDD HADS>8  0/8 had recurrence of IFN-MDD
Citalopram
120 (Comparison with prior IFN−α trial) Small average increase in HADS scores
Citalopram
107 Open label 14 vs 11 Average MADRS >10;  DSM-IV  2/14 developed IFN-MDD vs 7/11
History of affective disorder in the comparison group
Various Open label 10 vs 21 History of any DSM-IV affective disorder  DSM-IV 2/10 developed IFN-MDD vs 10/21
in the comparison group
Table II. Studies examining prevention of IFN-MDD using antidepressants. Three randomized placebo-controlled trials (RCT), and four open-label stud-
ies examining the prevention of major depressive disorder (MDD), diagnosed using criteria from the Diagnostic and Statistical Manual  of
Mental Disorders-IV (DMS-IV), the Hamilton Depression rating scale (HAM-D), or the Montgomery-Asberg Depression Rating Scale (MADRS). 
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more targeted use of SSRIs to prevent recurrence, lim-
iting prophylactic SSRI to those patients who are known
to have past MDD histories. 
However, all of these studies have been very limited in
size, and therefore power. Assessing all of the six pub-
lished prevention studies and our open-label data com-
bined—in a very exploratory type of meta-analysis—
15/97 (15%) patients receiving SSRIs prior to starting
IFN−α developed IFN-MDD, compared with 36/99
(36%). This is a significant difference, χ
2=8.2; P<0.001.
However, limiting the meta-analysis to the three RCTs,
10/55 (18%) subjects randomized to pretreatment
paroxetine developed IFN-MDD while 21/68 (31%) ran-
domized to placebo did. The trend is numerically similar
to the larger meta-analysis, but does not have the power
to be significant in a chi-square test (χ
2=1.98). 
At this point, only tentative conclusions are possible: (i)
Prophylactic SSRIs may plausibly cut in half the inci-
dence of IFN-MDD. To conclusively determine this,
however, will require a larger-size trial than those per-
formed to date; (ii) SSRIs may specifically benefit sub-
jects with either pre-existing depressive symptoms (ie,
subthreshold depression) and/or a history of prior MDD.
This is consistent either with studies of “indicated pre-
vention” in which patients with subthreshold depression
are prevented from worsening to full categorical MDD
by about 30%,
108-110 or with studies preventing recurrence
of MDD.
116-119 A more targeted prevention RCT would
be valuable to examine these two possibilities; (iii) Even
if SSRIs are found to be effective prophylactics for some
people, about 15% to 20% of patients still developed
IFN-MDD even when prescribed SSRIs, therefore anti-
depressants may not be universally effective. Other tar-
gets and approaches for prevention are needed; (iv)
Most importantly, about half of the patients with a his-
tory of MDD remain resilient even during IFN−α treat-
ment. Identifying the source of this resilience for poten-
tial replication in other patients would be beneficial. 
Modifiable risk factors for IFN-MDD
The goal for this work is preventative treatments that
can be targeted towards specifically mitigating those
mechanisms underlying vulnerability. Poor sleep quality
prior to IFN−α treatment may be one such risk fac-
tor.
121,122 Patients with scores greater than 10 on the
Pittsburgh Sleep Quality Index, a validated self-report
assessment of sleep quality,
123 were ten times more like
to subsequently develop IFN-MDD than patients sleep-
ing better than this.
122 This large effect size was evident
even when controlling for other depression symptoms.
It is also consistent with large epidemiological studies
wherein insomnia predicted the subsequent develop-
ment of MDD over follow-up intervals of 1 to 35
years.
124-127As many treatments for sleep exist, this may
be a potentially modifiable risk factor for preventing
IFN-MDD. This has previously been suggested for
MDD,
128 but may now be readily testable in patients
about to be treated with IFN−α.
There is also evidence that increased age may be another
risk factor for IFN-MDD,
129 although this is certainly not
a consistent finding.
130,131 Despite the fact that age itself is
not modifiable, this could indicate the presence of age-
related modifiable risk factors. Related to this, elevated
levels of inflammatory cytokines, such as interleukin-6
(IL-6), prior to IFN−α therapy have been associated with
subsequent IFN-MDD.
132,133Additionally, a polymorphism
in IL-6 that has been associated with increased IL-6 lev-
els is predictive of IFN-MDD.
134 In the subset of people
with increased IL-6 during IFN−α administration, the IL-
6 levels temporally predicted next month’s depression
symptoms.
133This is consistent with cross-sectional stud-
ies in which elevated IL-6 levels are associated with
MDD.
54,132,135-140Thus, increased IL-6 may be another plau-
sibly modifiable target for preventive intervention in
depressed individuals. Interestingly, IL-6 increases with
age but can be modified by diet
141 and/or exercise.
142,143
Potential premorbid risk factors for IFN-MDD that may
be modifiable through psychosocial interventions could
include social isolation
144 and neuroticism.
115,145 However,
when controlling for other premorbid risk factors, the effect
size for these is fairly small.
146Another risk factor may be a
hyperactive stress response in the hypothalamic-pituitary-
adrenal (HPA) axis.
147 Given the common association
between abnormalities in the HPA axis and MDD,
148-150 this
may also be a potentially useful predictive marker.
Interestingly, HPA axis responsiveness can be therapeuti-
cally modifiable by antidepressants.
151-154 It is therefore plau-
sible that patients with overactive HPA responses may be
the subjects who benefit most from antidepressant pro-
phylaxis. Consistent with this, stress-reactivity did correlate
with depressive symptoms prior to IFN−αtherapy
147—and
thus elevated stress-reactivity may be a potential predictor
of the need for “indicated” SSRI prevention.
Genetic polymorphisms within the serotonergic system
have also been associated with vulnerability to IFN-
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134,146,155Two studies have replicated the finding that
a short allele in the serotonin transporter robustly
increases risk for IFN-MDD.
134,146 Vulnerability to tryp-
tophan depletion has also been associated with poly-
morphisms in the 5-HT reuptake transporter.
59 Because
IFN-MDD has been associated with lowered tryptophan
levels during treatment,
57,91,93,156 this suggests that differ-
ences in serotonergic tone may leave some people vul-
nerable to IFN-MDD. It is also plausible that these are
the same subjects who may benefit from SSRI prophy-
laxis, a possibility that requires testing. 
Interestingly, gender has not been a consistent predictor
of IFN-MDD,
37,157,158 which suggests that IFN-MDD may
be partially distinct from some forms of MDD that are
unique to females. Also, as long as patients remain absti-
nent, a past history of drug and alcohol abuse is not pre-
dictive of increased risk.
15,37,131This suggests that risks for
drug and alcohol abuse are distinct from risk for IFN-
MDD. One critical implication is that a past history of
drug use, in remission, is not a contraindication to pre-
scribing IFN−α. Nonetheless, several leads are now sug-
gested by these various predictive risk factors, several of
which may be amenable to modification. The IFN-MDD
paradigm has now been used in several studies to exam-
ine whether SSRIs can prevent depression. It may now
be useful to determine whether other preventive treat-
ments are effective.
Other populations at selective risk for MDD
In summary, encouraging results indicate that: (i) specific
patients may be at elevated risk for IFN-MDD; (ii) this
vulnerability may be identifiable prior to IFN−α treat-
ment; (iii) some sources of this vulnerability (such as
poor sleep) may be modifiable; and (iv) therefore per-
sonalized prevention is testable and could become a real-
ity. Because of the high incidence of IFN-MDD in the
first few months of treatment, and the ability to recruit
nondepressed patients prior to IFN−α treatment, exam-
ining these possibilities appears to be practical and fea-
sible in this population. Several studies with prophylac-
tic SSRIs have already occurred. Furthermore, because
of the homologies between IFN-MDD and MDD in gen-
eral, any lessons learned from IFN-MDD may be trans-
latable to other types of MDD. As examples, MDD
occurs at higher rates in populations with multiple
chronic illnesses,
159 during bereavement,
160 in caregivers
of demented patients,
161 in stroke survivors,
162-164 in post-
partum mothers,
110,165,166 and there is preliminary evidence
that MDD incidence could potentially be reduced in
these settings.
161,167 Similar to IFN-MDD, most people in
these settings are resilient to developing MDD, with only
a subset who are vulnerable.
168
Conclusion
It remains an intriguing possibility that modifiable risk
factors identified for IFN-MDD may also be modifiable
risk factors in these other settings. Thus, targeting the
appropriate prevention to the appropriate patient may
be possible, and this may soon lead to the personalized
prevention of MDD. ❏
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Depresión mayor durante el tratamiento 
con -interferón: vulnerabilidad y 
prevención
El trastorno depresivo mayor (TDM) durante el tra-
tamiento con -interferón (IFN) puede presentarse
a los pocos meses de terapia y comparte muchas
características con otras formas de TDM. La mayo-
ría de los pacientes son resilientes al efecto lateral
de la depresión inducida por interferón (TDM-IFN),
pero el 15% a 40% es vulnerable. Varios estudios
han utilizado antidepresivos para prevenir la inci-
dencia de un episodio de TDM-INF y los resultados
sugieren que los antidepresivos profilácticos pue-
den ser empleados específicamente en quienes tie-
nen síntomas subumbrales pre-existentes y/o una
historia de episodios previos de TDM. Se han pro-
puesto varios potenciales marcadores de vulnera-
bilidad para el TDM-INF en la evaluación de pacien-
tes no depresivos antes de iniciar el αINF. Estos
incluyen una mala calidad del sueño, aumento pre-
mórbido de las citoquinas inflamatorias, polimor-
fismo genético en el sistema serotoninérgico, per-
sonalidad y apoyo social. El interjuego de estos
factores predice en forma importante quién está en
riesgo de un TDM-INF y señala varios blancos poten-
cialmente modificables para una prevención perso-
nalizada del TDM-INF.  
Dépression majeure au cours d’un 
traitement par interféron- : 
vulnérabilité et prévention
Un épisode dépressif majeur (EDM) peut survenir
au cours des premiers mois d’un traitement par
interféron- (IFN-), montrant  des similitudes avec
les autres formes de dépression caractérisées. La
plupart des patients présentent une résilience  à
cette dépression induite par l'interféron mais 15 à
40 % y sont vulnérables. Plusieurs études ayant uti-
lisé des antidépresseurs pour prévenir la survenue
d’un EDM lié à l’IFN (IFN-EDM) ont montré qu’une
prophylaxie antidépressive peut être utilisée spé-
cifiquement chez les patients ayant une sympto-
matologie dépressive infraclinique et/ou des anté-
cédents d' EDM. Des patients non dépressifs ont été
testés avec des marqueurs potentiels de susceptibi-
lité aux IFN-EDM avant de débuter un traitement
par IFN-α. Ils incluent un sommeil de mauvaise qua-
lité, une augmentation prémorbide des cytokines
inflammatoires, des polymorphismes génétiques du
système sérotoninergique, des éléments de la per-
sonnalité et de l’environnement social. L’interaction
de ces facteurs prédit fortement qui est à risque
d’IFN-EDM et constitue certaines cibles potentielle-
ment modifiables dans le cadre de la prévention
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